Contraception in Women With Sickle Cell Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

October 31, 2018

Study Completion Date

June 30, 2019

Conditions
Sickle Cell Disease
Interventions
DRUG

etonogestrel-releasing implant contraceptive

The etonogestrel implant will be inserted until the fifth day of the menstrual cycle . Anthropometric measurements will be performed , blood pressure measurement , application of pain questionnaire for the last three months, and collection of fasting blood in our clinic . After these measures , the ENG implant will be applied per researcher trained for such a procedure , following the recommendations outlined by the manufacturer. Women are instructed to return after 3, 6, 9, 12 months, fasting 8h , when they will be measured anthropometric measurements , blood collection, and delivery of pain questionnaires and standard of menstrual bleeding.

Trial Locations (2)

Unknown

Bahiana School of Medicne and Public Health, Salvador

14049-900

University of Sao Paulo, Ribeirão Preto

All Listed Sponsors
collaborator

Escola Bahiana de Medicina e Saude Publica

OTHER

lead

University of Sao Paulo

OTHER

NCT02594462 - Contraception in Women With Sickle Cell Disease | Biotech Hunter | Biotech Hunter